Heartflow Q3 2026: Revenue Surges 57% as Losses Nearly Vanish
As seen on the 24/7 Wall St. homepage on November 12, 2026.
Heartflow raised full-year revenue guidance for the second time this year, to $262 million to $264 million. Management says the path to profitability is getting clearer, and the loss is nearly gone.
Continue ReadingShow less
Heartflow posted Q3 2026 revenue of $72.9 million, beating the $65.2 million consensus estimate by nearly 12% and marking the third consecutive quarter of accelerating growth. The year-over-year revenue gain came in at 57.4%, fueled by rising U.S. case volume for both its FFRct and Plaque analyses. CEO John Farquhar called it the fastest pace of U.S. revenue growth in 11 quarters.
The adjusted loss per share came in at just $0.03, against a consensus estimate of $0.10, a beat of roughly 71%. Gross margin expanded to 83.6% from 76.5% a year ago, driven by case volume growth and AI-driven production productivity gains. The GAAP net loss narrowed to $11.5 million from $50.9 million in the prior-year quarter, though that earlier figure included a $32.1 million noncash warrant liability remeasurement.
Heartflow raised its full-year 2026 revenue guidance to $262 million to $264 million, representing 49% to 50% growth year-over-year. That is the second guidance increase of the year, up from a prior range of $246 million to $250 million. The company also lifted its non-GAAP gross margin target to approximately 82.5%, from approximately 82%.
Sponsored
As recently as Q2 2025, the reported loss of $1.10 per share badly missed a $0.21 estimate. By Q3 2026, the loss has shrunk to $0.03, well inside the already-improving consensus. Plaque Analysis activations are ramping ahead of plan, and management says the CCTA market remains significantly underpenetrated, leaving room for the installed base to keep expanding.
R&D spending rose to $29.5 million in the quarter from $17.3 million a year earlier, a sign that Heartflow is reinvesting its operating leverage. Cash and equivalents stood at $31.6 million, down sharply year-over-year. Investors will want to monitor the balance sheet alongside the profitability trajectory, particularly given ongoing litigation expenses and the company's stated risks around reimbursement coverage and customer concentration.
Mentioned: HTFL